miRNAs Potentially Involved in Post Lung Transplant-Obliterative Bronchiolitis: The Role of miR-21-5p.
bronchiolitis obliterans
chronic lung allograft dysfunction
in situ hybridization
miR-21-5p
microRNA
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
20 03 2021
20 03 2021
Historique:
received:
19
02
2021
revised:
12
03
2021
accepted:
17
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
25
2
2023
Statut:
epublish
Résumé
Epigenetic changes, including miRNAs deregulation, have been suggested to play a significant role in development of obliterative bronchiolitis (OB) in transplanted lungs. Many studies have tried to identify ideal candidate miRNAs and the downstream pathways implicated in the bronchiolar fibro-obliterative process. Several candidate miRNAs, previously indicated as possibly being associated with OB, were analyzed by combining the quantitative real time-polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH) of lung tissues of OB affected patients. Disease and OB-lesion-specific expression of miR-21-5p was confirmed and by computational analysis we were able to identify the network of genes most probably associated miR-21-5p in the context of OB fibrogenesis. Among all potentially associated genes, STAT3 had a very high probability score. Immunohistochemistry showed that STAT3/miR-21-5p were co-over expressed in OB lesions, thus, suggesting miR-21-5p could regulate STAT3 expression. However, miR-21-5p inhibition in cultures of bronchiolitis obliterans syndrome (BOS) derived myofibroblasts did not significantly affect STAT3 mRNA and protein expression levels. This study demonstrates the specificity of miR-21-5p over-expression in OB lesions and contributes to existing knowledge on the miR-21-5p downstream pathway. Activation of STAT3 is associated with miR-21-5p upregulation, however, STAT-3 network activation is most likely complex and miR-21-5p is not the sole regulator of STAT3.
Identifiants
pubmed: 33804639
pii: cells10030688
doi: 10.3390/cells10030688
pmc: PMC8003603
pii:
doi:
Substances chimiques
MIRN21 microRNA, human
0
MicroRNAs
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Foundation IRCCS Policlinico San Matteo, Pavia, Italy (Ricerca corrente grant)
ID : 935-rcr2018i-30 and748-rcr2013-13
Organisme : Department of Molecular Medicine of the University of Pavia (young research funds)
ID : FRG 2017
Références
Mol Carcinog. 2017 Apr;56(4):1227-1238
pubmed: 27805284
Nanomedicine (Lond). 2015 Jan;10(1):9-23
pubmed: 24559038
Respir Res. 2016 Sep 05;17(1):110
pubmed: 27596748
Transl Res. 2011 Apr;157(4):191-9
pubmed: 21420029
Theranostics. 2017 Jun 1;7(8):2287-2288
pubmed: 28740551
Nat Commun. 2017 Oct 24;8(1):1130
pubmed: 29066712
J Cell Physiol. 2017 Nov;232(11):2938-2945
pubmed: 28112397
J Clin Invest. 2017 May 1;127(5):1786-1797
pubmed: 28375153
J Oncol. 2019 Nov 30;2019:4216750
pubmed: 31885576
J Thorac Dis. 2017 Aug;9(8):2650-2659
pubmed: 28932572
Chest. 2011 Aug;140(2):502-508
pubmed: 21813529
CNS Neurosci Ther. 2012 Sep;18(9):722-8
pubmed: 22709411
Mol Cell. 2010 Aug 27;39(4):493-506
pubmed: 20797623
J Cell Mol Med. 2014 Jun;18(6):991-1003
pubmed: 24702795
J Asthma. 2013 Nov;50(9):960-4
pubmed: 23822889
Transpl Immunol. 2017 Jun;42:1-4
pubmed: 28457921
Mol Cancer Res. 2007 May;5(5):509-20
pubmed: 17510316
Int J Mol Sci. 2018 Aug 05;19(8):
pubmed: 30081609
Rheumatology (Oxford). 2018 Oct 1;57(10):1838-1850
pubmed: 29029263
Biomed Res Int. 2014;2014:521586
pubmed: 24991558
Physiol Genomics. 2008 Apr 22;33(2):139-47
pubmed: 18303086
Respir Res. 2013 Sep 24;14:95
pubmed: 24063588
J Exp Med. 2010 Aug 2;207(8):1589-97
pubmed: 20643828
Proc Am Thorac Soc. 2012 Jul;9(3):177-82
pubmed: 22802294
Kidney Int. 2016 Dec;90(6):1285-1297
pubmed: 27616741
Mol Diagn Ther. 2018 Apr;22(2):157-168
pubmed: 29335927
Blood. 2007 Aug 15;110(4):1330-3
pubmed: 17496199
BMC Bioinformatics. 2016 Apr 08;17:157
pubmed: 27059647
Curr Transplant Rep. 2016 Sep;3(3):185-191
pubmed: 28090432
PLoS One. 2016 Aug 26;11(8):e0161771
pubmed: 27564214
Front Oncol. 2020 Sep 25;10:577636
pubmed: 33072610
FASEB J. 2016 Jan;30(1):129-40
pubmed: 26324850
Arthritis Res Ther. 2016 Jan 13;18:11
pubmed: 26762516
Toxicology. 2019 Feb 15;414:57-67
pubmed: 30658076
Toxicol Appl Pharmacol. 2013 Nov 15;273(1):27-34
pubmed: 24004609
Physiol Rev. 2017 Apr;97(2):529-552
pubmed: 28151425
J Heart Lung Transplant. 2010 Oct;29(10):1159-64
pubmed: 20580267
Sci Rep. 2018 Jul 24;8(1):11167
pubmed: 30042393
FASEB J. 2020 Dec;34(12):15647-15658
pubmed: 33058239
Mol Cancer. 2013 Jun 01;12:50
pubmed: 23725032
Respir Res. 2018 Feb 06;19(1):24
pubmed: 29409529
Fibrogenesis Tissue Repair. 2013 Aug 29;6(1):16
pubmed: 23987664
Bioinformatics. 2010 Nov 15;26(22):2924-6
pubmed: 20861032
J Heart Lung Transplant. 1996 Jan;15(1 Pt 1):1-15
pubmed: 8820078